Loading...
BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancer
The androgen receptor (AR) is central to the initiation and progression of prostate cancer, even after castration. There has been some success in therapies targeting AR signaling which have been shown to extend survival in men with castration-resistant prostate cancer (CRPC). However, durable respon...
Saved in:
| Published in: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Taylor & Francis
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622075/ https://ncbi.nlm.nih.gov/pubmed/25535892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.962297 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|